The Programmed Cell Death 1 Ligand 2 pipeline drugs market research report outlays comprehensive information on the Programmed Cell Death 1 Ligand 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Programmed Cell Death 1 Ligand 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Unspecified Cancer. It also reviews key players involved in Programmed Cell Death 1 Ligand 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Programmed Cell Death 1 Ligand 2 pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, 6, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Programmed Cell Death 1 Ligand 2 overview
Programmed Cell Death 1 Ligand 2 (PD-L2) is a protein that in humans is encoded by the PDCD1LG2 gene. This is also known as CD273 which is an immune checkpoint receptor ligand and plays a role in negative regulation of the adaptive immune response. PD-L2 binds to its receptor PD-1and can activate pathways inhibiting TCR/BCR-mediated immune cell activation.
For a complete picture of Programmed Cell Death 1 Ligand 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
